Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Rachel ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, one of its top-sellers.

In 2024, gross and operating margins recovered while net margins continued to slide. The detailed performance ... Asian companies that is investing in biosimilars and hence is well-poised to ...

AbbVie has made ADCs a key part of its R&D strategy as it faces the loss of revenues caused by biosimilar competition to Humira (adalimumab), which saw sales slide by 37% to $2.23 billion in the ...

The PBM system intentionally blocks lower-cost, FDA-approved biosimilars from being available to patients. Biosimilars are the commonsense, bipartisan solution to out-of-control prescription drug ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core ...